Health Condition 1: null- Wuchereia bancrofti infected person
Conditions
Interventions
Intervention1: Albendazole and DEC: Arm 2 400 mg of Albendazole and 300mg of DEC Biannually orally single dose
Arm 3 800 mg of Albendazole and 300mg of DEC Annually orally single dose
Arm 4 800 mg o
Sponsors
Regional Medical Research Centre Chandrasekharpur Bhubaneswar
Eligibility
Inclusion criteria
Inclusion criteria: Treatment - Age 18 years to 55 years - Men and non-pregnant or non-breastfeeding women - Microfilarial levels >50 mf /ml - Willingness to spend 3 days in hospital - Willingness to undergo night time blood draws every 6 months for 2 years - Ability to understand and sign the informed consent - Hb levels for inclusion >9 g/dl - Normal Cr, ALT
Exclusion criteria
Exclusion criteria: Treatment â?? Non-volunteers â?? Age 55 years â?? Pregnancy or breast-feeding â?? Hgb â?? Cr > 1.2/100 ml â?? ALT > 30 U â?? Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a week of each drug administration â?? Serious medical illness â?? History of benzimidazole allergy â?? History of DEC allergy â?? Use of Albendazole or DEC within past 6 months â?? Unwillingness to comply with required study visits
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine whether increasing the Albendazole dose or the frequency of treatment with DEC /Albendazole is more effective than the current WHO-approved mass treatment regimen at clearing microfilariamia as assessed by night time microfilarial counts.Timepoint: Baseline,6,12,18and 24 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the effect of these treatments on adult worm burden in those subjects with detectable worm nests at baseline by ultrasound of adult worm nests at 12 and 24 months and the circulating antigen assay.Timepoint: Baseline,12 and 24 months | — |
Countries
India
Contacts
Public ContactDr B Dwibedi
Regional Medical Research Centre
Outcome results
None listed